Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTWXB3E)

• DTT Name: Hepatitis C virus NS3 helicase (HCV NS3) DTT Info
• Gene Name: HCV NS3

Molecule-Related Drug & Molecule List

5 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BILN-2061	DM2J36F	Hepatitis virus infection	1E50-1E51	Phase 2	[1]
GS-9451	DMF910Q	Chronic HCV-1 infection	1E51.1	Phase 2	[2]
GS-9857	DMYU6P5	Hepatitis C virus infection	1E51.1	Phase 2	[3]
ACH-2684	DMW6X0O	Hepatitis C virus infection	1E51.1	Phase 1	[4]
VBY-376	DMU263R	Hepatitis C virus infection	1E51.1	Phase 1	[5]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-605339	DMY7ZRA	Hepatitis C virus infection	1E51.1	Terminated	[6]

32 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2,4,6-Trihydroxy-3-nitro-N-tridecyl-benzamide	DMTVL9N	Discovery agent	N.A.	Investigative	[7]
Ac-Glu-Cha-Cys	DM6T09B	Discovery agent	N.A.	Investigative	[8]
AcAsp-D-Gla-Leu-Ile-Cha-Cys	DMT74F5	Discovery agent	N.A.	Investigative	[7]
AcAsp-D-Glu-Leu-Glu-Cha-Cys	DMDC71B	Discovery agent	N.A.	Investigative	[8]
AcAsp-Gla-Leu-Ile-Cha-Cys	DMXQATR	Discovery agent	N.A.	Investigative	[8]
AcAsp-Glu-Cha-Val-Prb-Cpg	DMHZ5W3	Discovery agent	N.A.	Investigative	[7]
AcAsp-Glu-Cha-Val-Prb-Cys	DMDH5EJ	Discovery agent	N.A.	Investigative	[7]
AcAsp-Glu-Dif-Glu-Cha-Cys	DMEB8UA	Discovery agent	N.A.	Investigative	[7]
AcAsp-Glu-Dif-Glu-Cha-Fab	DMPQ8Z9	Discovery agent	N.A.	Investigative	[7]
AcAsp-Glu-Dif-Ile-Cha-Cys	DM6IP17	Discovery agent	N.A.	Investigative	[8]
AcAsp-Glu-Dif-Ile-Cha-Cys-Iqc-Nle-Thr-TyrNH2	DM3W68X	Discovery agent	N.A.	Investigative	[7]
AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Cha-Asp-ValNH2	DMCIJ6Q	Discovery agent	N.A.	Investigative	[7]
AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Nle-Asp-ValNH2	DMA7ZSY	Discovery agent	N.A.	Investigative	[7]
AcAsp-Glu-Dif-Lys-Cha-Cys	DM6PZ45	Discovery agent	N.A.	Investigative	[8]
AcAsp-Glu-Leu-Glu-Cha-Cys	DMKDZH4	Discovery agent	N.A.	Investigative	[8]
AcAsp-Glu-Met-Glu-Cha-Cys	DMOMI91	Discovery agent	N.A.	Investigative	[8]
AcAsp-Glu-Met-Glu-Glu-Cys	DMIVFZE	Discovery agent	N.A.	Investigative	[7]
AcAsp-Glu-Met-Glu-Nal-Cyse	DMBGHX7	Discovery agent	N.A.	Investigative	[8]
AcDif-Glu-Cha-Cys	DMKDEWH	Discovery agent	N.A.	Investigative	[8]
AcDif-Ile-Cha-Cys	DM1DWCP	Discovery agent	N.A.	Investigative	[8]
AcGlu-Asp-Val-Val-Leu-Cys-Iqc-Nle-Thr-TyrNH2	DMAI43O	Discovery agent	N.A.	Investigative	[7]
AcGlu-Dif-Glu-Cha-Cys	DM0BV9I	Discovery agent	N.A.	Investigative	[8]
AcGlu-Dif-Ile-Cha-Cys	DMK6HGI	Discovery agent	N.A.	Investigative	[8]
Asp-D-Glu-Leu-Glu-Cha-Cys	DMEW37R	Discovery agent	N.A.	Investigative	[8]
Azapeptide	DM3BXUJ	Discovery agent	N.A.	Investigative	[9]
Boc-Ile-Leu-L-(difluoro)aminobutyric aid	DMG35MJ	Discovery agent	N.A.	Investigative	[7]
Cbz-Ile-Leu-L-(difluoro)aminobutyric acid	DMI53WR	Discovery agent	N.A.	Investigative	[7]
GNF-PF-3464	DMWAKHD	Discovery agent	N.A.	Investigative	[10]
PATULIN	DM0RV9C	Discovery agent	N.A.	Investigative	[7]
Ribavirin-TP	DM09NGV	Discovery agent	N.A.	Investigative	[11]
SCH-68631	DM4CI57	Discovery agent	N.A.	Investigative	[7]
SE RNA	DMYSKI0	Human immunodeficiency virus infection	1C62	Investigative	[12]

References

• [1] Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005 Apr;41(4):832-5.
• [2] Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients. Antimicrob Agents Chemother. 2012 October; 56(10): 5289-5295.
• [3] Clinical pipeline report, company report or official report of Gilead.
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses. 2010 August; 2(8): 1752-1765.
• [6] Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem.2014 Mar 13;57(5):1708-29.
• [7] Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
• [8] Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
• [9] Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease. Bioorg Med Chem Lett. 2002 Apr 8;12(7):1005-8.
• [10] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [11] ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy. Acta Biochim Pol. 2000;47(1):173-80.
• [12] Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.